Posted by Morningside Salon: Investing in the Healthcare Sector
7pm, Wednesday April 27
With a CAGR of 12%, healthcare is one of the fastest growing industries in China. Have you ever wondered what the key drivers of growth are? Or what the future of the healthcare industry looks like? CUAAHK and HKUST Business School cordially invites you to our next Morningside Salon discussion, with Ms. Nisa Leung, Managing Partner of Qiming Venture Partners. Nisa will share valuable insights from her successful career as a venture capitalist focusing on the Chinese healthcare market.
Event Details
|
Moderator |
Helen Chen, Head of External and Alumni Relations, HKUST Business School |
|
Date |
Wednesday, 27th April, 2022 |
|
Registration |
6:50 pm |
|
Discussion |
7:00 pm |
|
Q&A |
7:45 pm |
|
Conclusion |
8:00 pm |
|
Location |
Zoom (Zoom link will be sent to registered guests on the morning of the event) |
|
RSVP |
Please RSVP on this event page |
|
Event Contact |
Sean Lee |
About the Speaker
Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China with over 430 portfolio companies.
She sits on board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics (SSE:688185; HKSE:6185), dMed, Chain Medical Labs, Berry Oncology, Belief BioMed, ZhenGe, Valgen among others. Her other investments include Gan & Lee (SSE:603087), New Horizon Health (HKSE:6606), Venus MedTech (HKSE:2500), Aeonmed Medical, Berry Genomics (SZSE:000710), Broncus (HKSE:2216), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Kira Pharmaceutical, LIH, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Wuxi Leiming, MEDx, Cure Genetics, Goodwill (SSE:688246), SinoCell Tech (SSE:688520), Sino Biological (SZSE:301047), Apollomics, Sino United, Schrödinger (NASDAQ:SDGR), Shouti, Jacobio (HKSE:1167), Hope Medicine, Insilico Medicine, Alamar among others.
Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital.
Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019, 2020, 2021 and 2022 and named Best Women VCs List by Forbes China (#1 in 2022, #2 in 2021).
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an independent non-executive director of the Hong Kong Exchanges and Clearing Limited (“HKEX”) and Hong Kong Palace Museum.